BTIG Expects 55% Upside In Exact Sciences
The 35-percent sell-off in shares of EXACT Sciences Corporation (NASDAQ: EXAS) offer an attractive entry point, according to BTIG Research.
The molecular diagnostics product company's main product is Cologuard, which is used to detect colorectal cancer.
The Analyst
Analyst Sean Lavin upgraded Exact Sciences from Neutral to Buy with a $60 price target, suggesting 55-percent upside.
The Thesis
A second set of lung data did not meet expectations, impacting Exact Sciences' shares, Lavin said in a Tuesday note.
"This was negative news but we do not feel much value was in the stock for this future test. Still, this issue impacted shares," the analyst said.
Competitive blood test data was released, but BTIG does not believe the products are competitive in the near term "for many reasons," Lavin said.
While Exact Sciences' spend is increasing, Lavin said this isn't bad news. Some investors were surprised by the size of the company's salesforce growth and the lack of expense guidance for 2018, he said.
"This likely pressured shares, and while there is some risk expenses could grow faster than investors like, it does increase the likelihood each quarter of meeting or exceeding revenue estimates."
Exact Sciences will at least meet consensus expectations for the first quarter, despite expectations that the flu season dampened ordering, Lavin said. Flu-related softness is unlikely to impact the company's long-term value, the analyst said.
The Price Action
Exact Sciences shares had risen over 64 percent over the past year through Monday.
The stock was up nearly 4 percent at the time of publication Tuesday afternoon.
Related Links:
Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
BMO Capital Markets: BioXcel's AI Platform Provides Partially Derisked Drug Candidates
Photo courtesy of Exact Sciences.
Latest Ratings for EXAS
Apr 2018 | BTIG Research | Upgrades | Neutral | Buy |
Feb 2018 | Baird | Upgrades | Neutral | Outperform |
Feb 2018 | Benchmark | Downgrades | Buy | Hold |
View More Analyst Ratings for EXAS
View the Latest Analyst Ratings
See more from Benzinga
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
